241 related articles for article (PubMed ID: 24532241)
1. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
Queirolo P; Spagnolo F; Ascierto PA; Simeone E; Marchetti P; Scoppola A; Del Vecchio M; Di Guardo L; Maio M; Di Giacomo AM; Antonuzzo A; Cognetti F; Ferraresi V; Ridolfi L; Guidoboni M; Guida M; Pigozzo J; Chiarion Sileni V
J Neurooncol; 2014 May; 118(1):109-16. PubMed ID: 24532241
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
Altomonte M; Di Giacomo A; Queirolo P; Ascierto P; Spagnolo F; Bajetta E; Calabrò L; Danielli R; de Rosa F; Maur M; Chiarion-Sileni V; Ferrucci P; Giannarelli D; Testori A; Ridolfi R; Maio M
J Exp Clin Cancer Res; 2013 Oct; 32(1):82. PubMed ID: 24423086
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M
Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
[TBL] [Abstract][Full Text] [Related]
6. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K
N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA; Simeone E; Sileni VC; Pigozzo J; Maio M; Altomonte M; Del Vecchio M; Di Guardo L; Marchetti P; Ridolfi R; Cognetti F; Testori A; Bernengo MG; Guida M; Marconcini R; Mandalà M; Cimminiello C; Rinaldi G; Aglietta M; Queirolo P
J Transl Med; 2014 May; 12():116. PubMed ID: 24885479
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
9. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E; Gentilcore G; Giannarelli D; Grimaldi AM; Caracò C; Curvietto M; Esposito A; Paone M; Palla M; Cavalcanti E; Sandomenico F; Petrillo A; Botti G; Fulciniti F; Palmieri G; Queirolo P; Marchetti P; Ferraresi V; Rinaldi G; Pistillo MP; Ciliberto G; Mozzillo N; Ascierto PA
Cancer Immunol Immunother; 2014 Jul; 63(7):675-83. PubMed ID: 24695951
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
[TBL] [Abstract][Full Text] [Related]
12. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
13. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
Frenard C; Peuvrel L; Jean MS; Brocard A; Knol AC; Nguyen JM; Khammari A; Quereux G; Dreno B
J Neurooncol; 2016 Jan; 126(2):355-60. PubMed ID: 26511495
[TBL] [Abstract][Full Text] [Related]
14. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.
Jones PS; Cahill DP; Brastianos PK; Flaherty KT; Curry WT
Neurosurg Focus; 2015 Mar; 38(3):E5. PubMed ID: 25727227
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
[TBL] [Abstract][Full Text] [Related]
17. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Margolin K; Ernstoff MS; Hamid O; Lawrence D; McDermott D; Puzanov I; Wolchok JD; Clark JI; Sznol M; Logan TF; Richards J; Michener T; Balogh A; Heller KN; Hodi FS
Lancet Oncol; 2012 May; 13(5):459-65. PubMed ID: 22456429
[TBL] [Abstract][Full Text] [Related]
19. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
